178 related articles for article (PubMed ID: 38110715)
1. Multiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma.
Huang X; Su B; Li M; Zhou Y; He X
Sci Rep; 2023 Dec; 13(1):22472. PubMed ID: 38110715
[TBL] [Abstract][Full Text] [Related]
2. SLC17A2 Expression Correlates with Prognosis and Immune Infiltrates in Hepatocellular Carcinoma.
Wang Z; Chen X; Jiang Z
Comb Chem High Throughput Screen; 2022; 25(12):2001-2015. PubMed ID: 35081886
[TBL] [Abstract][Full Text] [Related]
3. Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.
Liu XN; Cui DN; Li YF; Liu YH; Liu G; Liu L
World J Gastroenterol; 2019 Aug; 25(30):4199-4212. PubMed ID: 31435173
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
[TBL] [Abstract][Full Text] [Related]
5. Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma.
Wei L; Lian B; Zhang Y; Li W; Gu J; He X; Xie L
BMC Genomics; 2014; 15 Suppl 1(Suppl 1):S13. PubMed ID: 24564407
[TBL] [Abstract][Full Text] [Related]
6. Construction of a disease-specific lncRNA-miRNA-mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma.
Zhang Q; Sun L; Zhang Q; Zhang W; Tian W; Liu M; Wang Y
Cancer Med; 2020 Dec; 9(24):9219-9235. PubMed ID: 33232580
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
[TBL] [Abstract][Full Text] [Related]
8. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
Xu K; Xia P; Chen X; Ma W; Yuan Y
Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
[TBL] [Abstract][Full Text] [Related]
9. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.
Grinchuk OV; Yenamandra SP; Iyer R; Singh M; Lee HK; Lim KH; Chow PK; Kuznetsov VA
Mol Oncol; 2018 Jan; 12(1):89-113. PubMed ID: 29117471
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma.
Deng T; Ye Q; Jin C; Wu M; Chen K; Yang J; Chen Z; Yu X; Chen G; Wang Y
Aging (Albany NY); 2021 Mar; 13(5):7481-7498. PubMed ID: 33686959
[TBL] [Abstract][Full Text] [Related]
11. Integrative analysis of the characteristics of lipid metabolism-related genes as prognostic prediction markers for hepatocellular carcinoma.
Zhu P; Li FF; Zeng J; Tang DG; Chen WB; Guo CC
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):116-126. PubMed ID: 33506899
[TBL] [Abstract][Full Text] [Related]
12. Low UGP2 Expression Is Associated with Tumour Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma.
Hu Q; Shen S; Li J; Liu L; Liu X; Zhang Y; Zhou Y; Zhu W; Yu Y; Cui G
Dis Markers; 2020; 2020():3231273. PubMed ID: 32733617
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
14. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
15. Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis.
Benfeitas R; Bidkhori G; Mukhopadhyay B; Klevstig M; Arif M; Zhang C; Lee S; Cinar R; Nielsen J; Uhlen M; Boren J; Kunos G; Mardinoglu A
EBioMedicine; 2019 Feb; 40():471-487. PubMed ID: 30606699
[TBL] [Abstract][Full Text] [Related]
16. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
Zhan K; Bai Y; Liao S; Chen H; Kuang L; Luo Q; Lv L; Qiu L; Mei Z
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278494
[TBL] [Abstract][Full Text] [Related]
18. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
Darpolor MM; Basu SS; Worth A; Nelson DS; Clarke-Katzenberg RH; Glickson JD; Kaplan DE; Blair IA
NMR Biomed; 2014 Apr; 27(4):381-9. PubMed ID: 24497316
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of Robust Hepatocellular Carcinoma Prognostic Subtypes Based on an Integrative Metabolite-Protein Interaction Network.
Chen D; Zhang Y; Wang W; Chen H; Ling T; Yang R; Wang Y; Duan C; Liu Y; Guo X; Fang L; Liu W; Liu X; Liu J; Otkur W; Qi H; Liu X; Xia T; Liu HX; Piao HL
Adv Sci (Weinh); 2021 Sep; 8(17):e2100311. PubMed ID: 34247449
[TBL] [Abstract][Full Text] [Related]
20. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
